Načítá se...
Oral platelet glycoprotein IIb/IIIa receptor inhibitors—part II
Although the hypothesis of benefit from prolonged oral IIb/IIIa inhibition was appealing, the large Phase III trials have uniformly shown there was no improvement in outcome. In addition, there was an increased mortality seen in patients treated with the oral IIb/IIIa inhibitor. This latter finding...
Uloženo v:
| Vydáno v: | Clin Cardiol |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wiley Periodicals, Inc.
2006
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6654522/ https://ncbi.nlm.nih.gov/pubmed/14524594 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.4960260903 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|